In conclusion, UCA1 has been demonstrated to enhance cetuximab resistance in CRC by binding and blocking miR‐495, thereby enabling the production of HGF and c‐MET, and subsequently activating the HGF/c‐MET axis.49 This evidence concerns the gene MET and colorectal carcinoma.